CellBion Co., Ltd. (KOSDAQ:308430)

South Korea flag South Korea · Delayed Price · Currency is KRW
23,300
+150 (0.65%)
At close: Dec 29, 2025
109.53%
Market Cap298.97B
Revenue (ttm)2.13B
Net Income (ttm)-7.55B
Shares Out12.83M
EPS (ttm)-589.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume128,173
Average Volume270,594
Open23,000
Previous Close23,150
Day's Range22,700 - 23,450
52-Week Range10,900 - 29,600
Betan/a
RSI56.82
Earnings DateMar 30, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 308430
Full Company Profile

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.

Financial Statements

News

There is no news available yet.